EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Pharmacological and Pharmaceutical Chemistry Perspectives on Optimizing Drug Combinations in Multidrug-Resistant Tuberculosis Patients

Iffat Ullah, Abdul Rauf, Pooja Chapagai

Innovative Research in Applied, Biological and Chemical Sciences · 2025

DOI: 10.62497/irabcs.157 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Innovative Research in Applied, Biological and Chemical Sciences, 2025. Verfasst von Iffat Ullah und 2 weiteren Autor:innen. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Multidrug-resistant tuberculosis (MDR-TB) poses a major global health challenge, requiring optimized drug combinations to improve outcomes.

Objective

To evaluate pharmacological and pharmaceutical chemistry perspectives in optimizing MDR-TB regimens, focusing on therapeutic effectiveness, resistance reduction, and clinical outcomes. Methodology: A prospective observational study was conducted at Bumrungrad International Hospital, Thailand, in collaboration with Prince of Songkla University from January 2022 to December 2023. A total of 406 confirmed MDR-TB patients were enrolled. Data included demographics, comorbidities, therapeutic drug monitoring, pharmaceutical chemistry profiling, in vitro drug–drug interaction assays, and clinical outcomes. Statistical analyses included chi-square, t-tests, and multivariate logistic regression.

Results

Of 406 patients, 243 (59.85%) were male and 163 (40.15%) female. Diabetes mellitus (21.92%) and HIV co-infection (6.65%) were significantly associated with poor outcomes (p < 0.001). Therapeutic drug monitoring showed optimal levofloxacin and bedaquiline levels in 73.40% and 79.80% of patients, respectively, both significantly linked to treatment success (p = 0.020 and p = 0.010). In vitro assays revealed synergy for levofloxacin–linezolid (62.81%) and linezolid–bedaquiline (57.14%). At six months, sputum culture conversion reached 84.00%, with overall treatment success in 78.82% (320/406). Early culture conversion (AOR 3.24, p < 0.001), absence of diabetes (AOR 2.11, p = 0.001), and adequate levofloxacin exposure (AOR 1.89, p = 0.004) were independent predictors of success. Adverse drug reactions occurred in 220 patients (54.19%), mostly gastrointestinal (21.18%) and neuropathy (12.81%), but only 3.45% required permanent drug withdrawal.

Conclusion

Integrating pharmacological monitoring and pharmaceutical chemistry insights enhances regimen optimization and improves MDR-TB treatment outcomes.

Zitieren

APA

Ullah, I., Rauf, A., & Chapagai, P. (2025). Pharmacological and Pharmaceutical Chemistry Perspectives on Optimizing Drug Combinations in Multidrug-Resistant Tuberculosis Patients. Innovative Research in Applied, Biological and Chemical Sciences. https://doi.org/10.62497/irabcs.157

Vancouver

Ullah I, Rauf A, Chapagai P. Pharmacological and Pharmaceutical Chemistry Perspectives on Optimizing Drug Combinations in Multidrug-Resistant Tuberculosis Patients. Innovative Research in Applied, Biological and Chemical Sciences. 2025. doi:10.62497/irabcs.157

BibTeX
@article{Ullah2025,
  author = {Ullah, Iffat and Rauf, Abdul and Chapagai, Pooja},
  title = {Pharmacological and Pharmaceutical Chemistry Perspectives on Optimizing Drug Combinations in Multidrug-Resistant Tuberculosis Patients},
  journal = {Innovative Research in Applied, Biological and Chemical Sciences},
  year = {2025},
  doi = {10.62497/irabcs.157}
}
Kostenlos starten →